Sino Biopharmaceutical (HK:1177) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical has announced positive results from its Phase III study of Benmelstobart Injection combined with chemotherapy, followed by Anlotinib Hydrochloride Capsules as a first-line treatment for advanced squamous non-small cell lung cancer. The interim analysis showed significant improvement in progression-free survival compared to the existing treatment, marking a promising development for patients with this challenging cancer subtype. The company plans to submit a marketing application for this new indication soon, which could offer new hope for cancer treatment.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.